Lately new improvements in cytogenetic, immunophenotyping and molecular biology have significantly propelled our comprehension of leukemia. Tragically, customary morphologic assessment of intense myeloblastic leukaemia utilizing the French-American-British characterization corresponds ineffectively with a large portion of this new data and does not anticipate the reaction to treatment. In this audit, we focus on uses of molecular biologic procedures to the determination of leukaemia and examine utilization of this innovation to identify the insignificant lingering illness. We at that point present an amended grouping for intense myeloblastic leukaemia as indicated by whether myelodysplasia-like highlights are available or lacking. Cases may then be additionally characterized utilizing French-American-British morphology and different parameters. This grouping seems to relate better with new biologic information and with remedial reaction.